The development of new blood vessels, termed as angiogenesis, is essential to embryonic growth and throughout life for physiological repair processes. The field of angiogenesis research was established approximately in 1970s by the Folkman hypothesis that tumor growth is angiogenesisdependent [1] . In addition to the tumor growth, another promising field where angiogenesis has drawn attention as a critical target is cardiovascular diseases [2] . Therefore, inhibiting angiogenesis is a promising strategy for treating diseases like cancer, while promoting angiogenesis may benefit the ischemic diseases such as myocardial infarction. Molecular insights into these processes and new therapeutic approaches are therefore particularly promising tools to understand the underlying pathologies and expand the available therapeutic options in abnormal angiogenesis. This special issue on angiogenesis highlights recent advances in our understanding of the molecular and cellular mechanisms of neovascularization. The summary of this special issue could be found in Figure 1 .
With more bioassays and preclinical experiments performed, progress in understanding the relationship between tumor growth and angiogenesis has created a new perspective on therapeutic angiogenesis. Metformin is one of the most efficacious and safe front-line antidiabetics for type 2 diabetes In general, this special issue on angiogenesis covered both excessive angiogenesis and insufficient angiogenesis (Figure 1 ). Either the reports or the reviews on angiogenesis presented in this issue will provide a further understanding about the real role of angiogenesis in cardiovascular diseases or cancer.
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